Novavax agrees on expansion of COVID-19 vaccine production in South Korea

SK Bioscience Co

22/05/2021 17:56

May 22 (Reuters) - Novavax Inc  NVAX.O  said on Saturday it
has signed an agreement with South Korea's SK Bioscience Co Ltd
 302440.KS  and the government to expand its production of
vaccines, including the U.S. drug developer's protein-based
COVID-19 vaccine candidate. 
    The latest agreement is in addition to an existing
manufacturing and licensing deal, intended to provide wider
access to NVX-CoV2373 in South Korea and globally, Novavax said
in a press release  urn:newsml:reuters.com:*:nPn4gH9dPa. 
    

 (Reporting by Maria Ponnezhath in Bengaluru; editing by Diane
Craft)
 ((Maria.Ponnezhath@thomsonreuters.com; +91 8061822749;))